Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 0.59 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.51 |
| ▸ | TNF | P01375 | 3/20 | 0.50 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062549 | 0.90 | CYP19A1 (0.59) | CYP19A1PBRM1AKR1B1MAPK14TNF | |
| SCHEMBL4051243 | 0.83 | TYMS (0.43) | CYP19A1AKR1B1MAPK14MIFMAOB | |
| SCHEMBL13771200 | 0.81 | CYP19A1 (0.41) | CYP19A1PBRM1AKR1B1MAPK14TNF | |
| SCHEMBL11089109 | 0.80 | TDP1 (0.69) | CYP19A1PBRM1AKR1B1MAPK14MIF | |
| SCHEMBL4062450 | 0.80 | CES1 (0.61) | CYP19A1TNFMIFMAOBTDP1 | |
| SCHEMBL4053805 | 0.78 | MAPT (0.49) | TDP1 | |
| SCHEMBL2317919 | 0.74 | AKR1B1 (0.59) | PBRM1AKR1B1MAPK14MIFMAOB | |
| SCHEMBL4061889 | 0.74 | PBRM1 (0.50) | CYP19A1PBRM1AKR1B1MAPK14TNF | |
| SCHEMBL11684328 | 0.72 | AKR1B1 (0.64) | PBRM1AKR1B1MAPK14MIFMAOB | |
| SCHEMBL8756228 | 0.72 | MAOA (0.59) | CYP19A1PBRM1AKR1B1MAPK14TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
| EP-1560834-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043966-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LTA4H, LTC4S, LTB4R2 | CYP19A1 1505/4885PBRM1 3425/4885AKR1B1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.